Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Tadatoshi KINOSHITA

Changes of Tissue Factor and Thrombomodulin Levels in Isolated Leukemic Cells From a Patient With Acute Promyelocytic Leukemia During All-Trans Retinoic Acid Therapy

Japanese Journal of Thrombosis and Hemostasis

1996

English

Multicenter Clinical Study of a Highly Purified Porcine Factor VIII Concentrate [MTI-9002 (Hyate: C)] in Hemophilia a Patients With Inhibitor

Japanese Journal of Thrombosis and Hemostasis

1991

English

Ultrastructual Study of LAV/HTLV-III in Hemophilia a With AIDS.

Blood & Vessel

1987

English

Related publications

4-Oxo Retinoic Acid for Refractory Acute Promyelocytic Leukemia in Children With All-Trans Retinoic Acid Therapy.

Journal of Nutritional Science and Vitaminology

English

Matrine Cooperates With All-Trans Retinoic Acid on Differentiation Induction of All-Trans Retinoic Acid-Resistant Acute Promyelocytic Leukemia Cells (NB4-LR1): Possible Mechanisms

Pharmaceutical Science

English

Additional Chromosome Abnormalities in Patients With Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid and Chemotherapy

Haematologica

Hematology

2009

English

Epigallocatechin-3-Gallate Promotes All-Trans Retinoic Acid-Induced Maturation of Acute Promyelocytic Leukemia Cells via PTEN

International Journal of Oncology

Cancer Research

Oncology

2017

English

All‐ Trans ‐Retinoic Acid Pharmacology and Its Impact on the Treatment of Acute Promyelocytic Leukemia

English

Pharmacogenomic Analysis of Acute Promyelocytic Leukemia Cells Highlights CYP26 Cytochrome Metabolism in Differential All-Trans Retinoic Acid Sensitivity

English

Pseudotumor Cerebri Associated With All-Trans Retinoic Acid Treatment in Female Patients With Acute Promyelocytic Leukemia: A Case Series

Biology of Blood and Marrow Transplantation

Transplantation

Hematology

2015

English

All-Trans Retinoic Acid and Arsenic Trioxide Fail to Derepress the Monocytic Differentiation Driver Irf8 in Acute Promyelocytic Leukemia Cells

Cell Death and Disease

Molecular Neuroscience

English

Successful Continuous Treatment With All-Trans Retinoic Acid for Acute Promyelocytic Leukemia; Secondary Malignancy After the Treatment of Osteosarcoma.

Internal Medicine

Medicine

1994

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Tadatoshi KINOSHITA

Changes of Tissue Factor and Thrombomodulin Levels in Isolated Leukemic Cells From a Patient With Acute Promyelocytic Leukemia During All-Trans Retinoic Acid Therapy

Multicenter Clinical Study of a Highly Purified Porcine Factor VIII Concentrate [MTI-9002 (Hyate: C)] in Hemophilia a Patients With Inhibitor

Ultrastructual Study of LAV/HTLV-III in Hemophilia a With AIDS.

Related publications

4-Oxo Retinoic Acid for Refractory Acute Promyelocytic Leukemia in Children With All-Trans Retinoic Acid Therapy.

Matrine Cooperates With All-Trans Retinoic Acid on Differentiation Induction of All-Trans Retinoic Acid-Resistant Acute Promyelocytic Leukemia Cells (NB4-LR1): Possible Mechanisms

Additional Chromosome Abnormalities in Patients With Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid and Chemotherapy

Epigallocatechin-3-Gallate Promotes All-Trans Retinoic Acid-Induced Maturation of Acute Promyelocytic Leukemia Cells via PTEN

All‐ Trans ‐Retinoic Acid Pharmacology and Its Impact on the Treatment of Acute Promyelocytic Leukemia

Pharmacogenomic Analysis of Acute Promyelocytic Leukemia Cells Highlights CYP26 Cytochrome Metabolism in Differential All-Trans Retinoic Acid Sensitivity

Pseudotumor Cerebri Associated With All-Trans Retinoic Acid Treatment in Female Patients With Acute Promyelocytic Leukemia: A Case Series

All-Trans Retinoic Acid and Arsenic Trioxide Fail to Derepress the Monocytic Differentiation Driver Irf8 in Acute Promyelocytic Leukemia Cells

Successful Continuous Treatment With All-Trans Retinoic Acid for Acute Promyelocytic Leukemia; Secondary Malignancy After the Treatment of Osteosarcoma.